Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript
Immuneering (US:IMRX) Seeking Alpha·2026-01-07 23:47PresentationWelcome to the Immuneering conference call to discuss the positive 12-month overall survival update from the company's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients. [Operator Instructions] As a reminder, this call is being recorded today, Wednesday, January 7, 2026. I would now like to turn the conference over to Courtney Dugan, Vice President, Head of Investor Relations. Please go ahead.Courtney Dugan Thank you, operator. Joining us on the call today from Imm ...